IONS SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

News

TYPE

HEADLINE

FILED AT

8-K

NEWIonis Pharmaceuticals Reports Q3 2026 Financial Results

Nov 9, 2026

8-K

Ionis and Roche Announce Positive Phase 3 Data for Sefaxersen in IgA Nephropathy

Oct 23, 2026

8-K

Ionis and GSK Announce U.S. FDA Approval of Hibsago (bepirovirsen) for Chronic Hepatitis B

Oct 21, 2026

8-K

Ionis and Roche Announce Positive Phase 3 Interim Results for Sefaxersen in IgA Nephropathy

Sep 23, 2026

8-K

Novartis and Ionis Announce Phase 3 Lp(a)HORIZON Results for Pelacarsen

Sep 4, 2026

8-K

FDA Approves ZANVASTRO™ (zilganersen) as First Disease-Modifying Treatment for Alexander Disease

Sep 4, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

SHELF OFFERING | Shares amount: 11,500,000 | Share price: $43.50 | Offering amount: $10,327,000.00 | Bank: Morgan Stanley, Goldman Sachs & Co. LLC

Sep 10, 2024

424B5

Shares amount: 10,663,254 | Offering amount: $500,000,000.00 | Bank: Morgan Stanley, Goldman Sachs & Co. LLC

Sep 9, 2024

424B7

1,631,435 Shares of Common Stock

Apr 21, 2017

424B5

9,000,000 Shares

May 9, 2013

424B5

9,000,000 Shares

May 7, 2013

424B3

53,267

Feb 8, 2008

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jul 31, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jul 30, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 5, 2024

S-3ASR

Common Stock

Nov 24, 2023

S-8

Registration

Aug 10, 2023

S-8

6,700,000 shares

Aug 5, 2021

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 23, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 23, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 25, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 25, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 25, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 25, 2024

Ownerships

TYPE

HEADLINE

FILED AT

Devers Shannon L. (Reporting)

Oct 19, 2026

Swayze Eric (Reporting)

Oct 19, 2026

144

Form 144 - Report of proposed sale of securities

Oct 16, 2026

BENNETT C FRANK (Reporting)

Sep 2, 2026

O'NEIL PATRICK R. (Reporting)

Sep 2, 2026

Monia Brett P (Reporting)

Sep 2, 2026

Other

TYPE

HEADLINE

FILED AT

LETTER

Form UPLOAD - SEC-generated letter

Jan 26, 2021

CORRESP

Form CORRESP - Correspondence

Jan 14, 2021

LETTER

Form UPLOAD - SEC-generated letter

Dec 30, 2020

CT ORDER

Form CT ORDER - Confidential treatment order

Dec 3, 2020

CORRESP

Form CORRESP - Correspondence

Sep 24, 2020

CT ORDER

Form CT ORDER - Confidential treatment order

Mar 24, 2020

Ionis Pharmaceuticals, Inc. IONS · SEC Filings